Antiobesity Market Growth Outlook Through 2024-2033

Overview and Scope
The anti-obesity drugs refer to the medications that are used to lower or regulate weight of a patient. These drugs interfere with one of the body’s basic functions, controlling weight, by affecting either appetite or calorie absorption. Dieting (a healthy diet and caloric restriction) and exercise continue to be the main therapeutic approaches for overweight and obese people.

Sizing and Forecast
The antiobesity market size has grown rapidly in recent years. It will grow from <b>$3.38 billion in 2023 to $3.76 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. </b> The growth in the historic period can be attributed to increasing obesity prevalence, awareness and education, lifestyle changes, government initiatives.

The antiobesity market size is expected to see rapid growth in the next few years. It will grow to <b>$5.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. </b> The growth in the forecast period can be attributed to market expansion, globalization. Major trends in the forecast period include research and development, patient-centric approaches, insurance coverage, technological advancements, digital health and telemedicine, novel drug therapies, bariatric surgery advancements, otc (over-the-counter) solutions, behavioral interventions, nutritional and weight management apps.

To access more details regarding this report, visit the link:

Segmentation & Regional Insights
The antiobesity market covered in this report is segmented –

1) By Drug Class: Peripherally acting anti obesity drugs, Centrally acting anti obesity drugs
2) By Type: Prescription Drugs (Rx), OTC Drugs
3) By Medication: Monotherapies, Polytherapies

<b>North America</b> was the largest region in the anti-obesity market in 2023. <b>Middle East</b> is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

Major Driver Impacting Market Growth
Obesity is a major public health concern globally. Globally, the prevalence rate of obesity is increasing every year. For instance, in May 2022, according to the World Obesity Atlas, a UK-based obesity organization, globally, it is estimated that more than 1 billion people will be suffering from obesity by 2030. This can be attributed to increased consumption of processed and unhealthy food, lack of physical activity, and lack of awareness of the risks of obesity. As a result, the demand for anti-obesity drugs is bound to increase in the future thus, driving the market growth.

Key Industry Players
Major companies operating in the antiobesity market include <b>F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.</b>

The antiobesity market report table of contents includes:

1. Executive Summary
2.Antiobesity  Market Characteristics
3.Antiobesity Market Trends And Strategies
4.Antiobesity  Market analysis
5.Antiobesity  Market Size And Growth
6.Antiobesity  Segmentation
7.Antiobesity  Regional And Country Analysis
27.Antiobesity  Competitive Landscape And Company Profiles
28.Antiobesity  Key Mergers And Acquisitions
29.Antiobesity  Future Outlook and Potential Analysis


  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Boehringer Ingelheim GmbH
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Takeda Pharmaceutical Company Limited

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
Healthcare Blog:
Global Market Model:

Leave a Reply

Your email address will not be published. Required fields are marked *